Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs LAG 525 (Primary) ; Spartalizumab (Primary)
- Indications Adenocarcinoma; Diffuse large B cell lymphoma; Gastric cancer; Haematological malignancies; Lymphoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Therapeutic Use
- Acronyms Module 9
- Sponsors Novartis Pharmaceuticals
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 04 Mar 2018 Planned End Date changed from 30 Jan 2021 to 1 Feb 2021.
- 04 Mar 2018 Planned primary completion date changed from 30 Jan 2021 to 30 Jan 2020.